New 2-Aryloxy-3-phenyl-propanoic Acids As Peroxisome Proliferator-Activated Receptors alpha/gamma Dual Agonists with Improved Potency and Reduced Adverse Effects on Skeletal Muscle FunctionFracchiolla, G., Laghezza, A., Piemontese, L., Tortorella, P., Mazza, F., Montanari, R., Pochetti, G., Lavecchia, A., Novellino, E., Pierno, S., Conte Camerino, D., Loiodice, F.
(2009) J Med Chem 52: 6382-6393
- PubMed: 19775169
- DOI: 10.1021/jm900941b
- Structures With Same Primary Citation
- PubMed Abstract:
- Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design
Montanari, R., Saccoccia, F., Scotti, E., Crestani, M., Godio, C., Gilardi, F., Loiodice, F., Fracchiolla, G., Laghezza, A., Tortorella, P., Lavecchia, A., Novellino, E., Mazza, F., Aschi, M., Pochetti, G.
(2008) J Med Chem 51: 7768
The preparation of a new series of 2-aryloxy-3-phenyl-propanoic acids, resulting from the introduction of a linker into the diphenyl system of the previously reported PPARalpha/gamma dual agonist 1, allowed the identification of new ligands with impr ...
The preparation of a new series of 2-aryloxy-3-phenyl-propanoic acids, resulting from the introduction of a linker into the diphenyl system of the previously reported PPARalpha/gamma dual agonist 1, allowed the identification of new ligands with improved potency on PPARalpha and unchanged activity on PPARgamma. For the most interesting stereoisomers S-2 and S-4, X-ray studies in PPARgamma and docking experiments in PPARalpha provided a molecular explanation for their different behavior as full and partial agonists of PPARalpha and PPARgamma, respectively. Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy.
Dipartimento Farmaco-Chimico, Università degli Studi di Bari, via Orabona 4, 70126 Bari, Italia.